Cancer Stem Cells in Chronic Myelogenous LeukemiaGabriella Marfe1* and Carla Di Stefano2
- Corresponding Author:
- Dr. Gabriella Marfe
PhD, Department of Biochemistry and Biophysics
Second University of Naples, Via De Crecchio 7, Naples 80138, Italy
E-mail: [email protected]
Received Date: July 29, 2014; Accepted Date: September 4, 2014; Published Date: September 24, 2014
Citation: Marfe G, Stefano CD (2014) Cancer Stem Cells in Chronic Myelogenous Leukemia. J Leuk (Los Angel) 2:159. doi:10.4172/2329-6917.1000159
Copyright: ©2014 Marfe G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chronic Myeloid Leukaemia (CML) is a haematological malignancy that is identified by the presence of a fusion oncogene, BCR-ABL, which is a constitutive tyrosine kinase. The discovery of Tyrosine Kinase Inhibitors (TKIs) over that past decade has resulted in significantly improved survival rates and disease management in CML patients. However, a subpopulation of BCR-ABL1+ cells in the niche are found which exhibit stem cell-like features, such as self-renewal and quiescence. These CML stem cells (LSCs) have been shown to be insensitive to TKIs treatment and are capable of deriving the disease during the relapse. Consequently, the elimination of LSCs is a primary goal of current research.